i(3)so3-galactosylceramide and Pneumonia--Viral

i(3)so3-galactosylceramide has been researched along with Pneumonia--Viral* in 1 studies

Other Studies

1 other study(ies) available for i(3)so3-galactosylceramide and Pneumonia--Viral

Article	Year
Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. Medical hypotheses, 2020, Volume: 143 Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore, a trial giving fenofibrate to patients with corona virus infection is recommended. Topics: Adult; Aging; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Fenofibrate; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pandemics; Pneumonia, Viral; PPAR alpha; SARS-CoV-2; Sulfoglycosphingolipids; Virus Internalization	2020

Article

Year

Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.

Medical hypotheses, 2020, Volume: 143

Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore, a trial giving fenofibrate to patients with corona virus infection is recommended.

Topics: Adult; Aging; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Fenofibrate; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pandemics; Pneumonia, Viral; PPAR alpha; SARS-CoV-2; Sulfoglycosphingolipids; Virus Internalization

2020